Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model

AIM: Dipeptidyl peptidase IV (DPP-IV) inhibition to modulate the incretin effect is a proven strategy to treat type 2 diabetes mellitus. The present study describes the pharmacological profile of a novel DPP-IV inhibitor RBx-0128, as an antidiabetic agent. MATERIAL AND METHODS: DPP-IV assay was carr...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Joseph A., Kumar, Pucha S., Singh, Shuchita, Surender, A., Roy, Subhasis, Khanna, Vivek, Sethi, Sachin, Pal, Chanchan, Sharma, Lalima, Benjamin, Biju, Mittra, Shivani, Sattigeri, Jitendra, Bansal, Vinay S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523506/
https://www.ncbi.nlm.nih.gov/pubmed/23248408
http://dx.doi.org/10.4103/0253-7613.103298

Ejemplares similares

Ejemplares similares